Nov. 18, 2020
GNS561’s successful phase 1b trial completed
Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
July 22, 2020
GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
18 June, 2020
Our COVID-19 research Project supported by the French Government
Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
April 6, 2020
COVID-19, GNS561’s Assault begins in France !
Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…
Read More
January 13, 2020
ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology
Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…
Read More
December 16, 2019
GNS561 to treat pancreas or colorectal cancer with liver metastasis
GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…
Read More
November 14, 2019
Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor
Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…
Read More
September 25, 2019
Invest in the Future of Health Biotech, European Biotech Week
Invest in the Future of Health Biotech during the European Biotech Week 2019 (Brussels) …
Read More
June 3, 2019
S.A.B Meeting in Chicago, during ASCO 2019
Scientific Advisory Board Meeting during ASCO 2019 Chicago, USA, June 3, 2019 — Genoscience…
Read More
April 17, 2019
Chaim Hurvitz, New Board of Directors Member
Chaim Hurvitz, New Board of Directors Member Chaim Hurvitz has joined Genoscience Pharma Board…
Read More
